期刊文献+

二肽基肽酶-4(DPP-4)抑制剂与心血管系统保护作用 被引量:6

下载PDF
导出
摘要 随着2型糖尿病的治疗方法不断发展,近期二肽基肽酶-4(DPP-4)抑制剂成为新型降糖药物,目前主要有西格列汀、维格列汀、沙格列汀和阿格列汀等。成为新型药物的作用机制取决于它可以起到抑制DPP-4酶活性的作用,DPP-4在生理条件下能分解胰高血糖素样肽-1(GLP-1)和葡糖依赖性促胰岛素多肽(GIP)。
作者 朱恩波
出处 《中国实验诊断学》 2016年第6期1042-1044,F0003,共4页 Chinese Journal of Laboratory Diagnosis
  • 引文网络
  • 相关文献

二级参考文献24

  • 1YangZ, MingXF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006; 4: 53-65.
  • 2Bauer V, Sotnikova R. Nitric oxide -- the endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys 2010; 29: 319-40.
  • 3Stankevicius E, Kevelaitis E, Vainorius E, Simonsen U. Role of nitric oxide and other endothelium-derived factors. Medicina (Kaunas) 2003; 39: 333-41.
  • 4Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
  • 5Drucker D J, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
  • 6Meier J J, Nauck MA. Incretinsand the development of type 2 diabetes. Curr Diab Rep 2006; 6: 194-201.
  • 7Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, etal. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-23.
  • 8Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7: 1055-64.
  • 9Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vaso- relaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-6.
  • 10Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nystrom T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept 2009; 157: 8-13.

共引文献16

同被引文献79

引证文献6

相关主题

;
使用帮助 返回顶部